I am the founding Vice President of Thielsen Capital. I leads the firm's pipeline, due diligence, and IC efforts. At Thielsen Capital we work with Life Science Tools startups to build high performance teams and focus on the early commercialization of the product. I help with Financial Modeling, Hiring Strategy, IP Evaluation and PMF. I regularly work with new founders months before investment to discuss company strategy for getting to the next funding round or for academic founders the path to spin out a company from academia.

Analyzed the effect of SARS-CoV-2 variant evolution on vaccine induced humoral immunity resulting in one first author paper currently under review at Cell Reports Medicineo Cloned and produced over 200 individual plasmids and pseudoviruses to assess escape of individual SARS-CoV-2 mutants and variants throughout the pandemic using a high throughput neutralization assay with a liquid handling roboto Performed viral RNA extractions and qPCR to determine infectivity of pseudovirusesDetermined the epitope targets underlying broadly neutralizing antibodies responses to Sarbecoviruses resulting in another first author manuscript currently in productiono Tracked correlates of broadly neutralizing responses against diverse SARS-CoV-2 variantso Developed novel depletion assays to determine the contributions to neutralization breadth of epitope specific antibodiesIdentified, isolated, and characterized novel broadly neutralizing antibodies against Coronaviruses, resulting in a third first author manuscript in preparationo Designed a highly selective novel flow cytometry staining protocol to isolate antigen specific single memory B cells in <1 weeko Developed an effective amplification protocol to go from single B-Cell to antibody production in 1 week using reverse transcription, whole transcriptome amplification and ligation independent cloning

I produced, characterized, and designed self assembling protein nanoparticles vaccines that were used in trials against Malaria parasite infection.